CXCL9 and ovarian cancer: For instance, in BRCA1-mut ovarian cancer, KTR14, KRT16, CXCL9, and CFD were highly upregulated (more than 4-fold change), and in BRCA2-mut ovarian cancers, TSPAN7 and CDKN2C were clearly upregulated (more than 2-fold change) (Figure 1B).